Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport plus TOT surgery versus TOT surgery alone for mixed urinary incontinence
IRCT20130306012728N7Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-blind trial of botulinum toxin type A in Mixed incontinence (MUI) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Response rate to treatment of urinary incontinence, ICIQ score and 1 more. Started Jan 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Mixed incontinence (MUI)
Beyond the preview
Go deeper on IRCT20130306012728N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130306012728N7.